Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Generic TAF/FTC/DTG in Virologically Suppressed HIV Adults
NCT03727152Phase 3Completed
- Sponsor
- HIV-NAT
- Start
- May 2019
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tenofovir alafenamide, emtricitabine, dolutegravir in human immunodeficiency virus infection (HIV), sponsored by HIV-NAT. Started May 2019; status: completed.
02
Drugs
tenofovir alafenamideemtricitabinedolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03727152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03727152.